Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
After finishing at $136.04 in the prior trading day, Abbott Laboratories (NYSE: ABT) closed at $136.62, up 0.43%. In other words, the price has increased by $0.43 from its previous closing price. On the day, 4.84 million shares were traded. ABT stock price reached its highest trading level at $137.49 during the session, while it also had its lowest trading level at $134.95.
Ratios:
Our goal is to gain a better understanding of ABT by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 32.65 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 35.10. For the most recent quarter (mrq), Quick Ratio is recorded 1.30 and its Current Ratio is at 1.82. In the meantime, Its Debt-to-Equity ratio is 0.27 whereas as Long-Term Debt/Eq ratio is at 0.26.
On June 16, 2025, Leerink Partners started tracking the stock assigning a Market Perform rating and target price of $143. On October 08, 2024, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $130.Oppenheimer initiated its Outperform rating on October 08, 2024, with a $130 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 08 ’25 when Boudreau Philip P sold 5,550 shares for $134.55 per share. The transaction valued at 746,758 led to the insider holds 51,003 shares of the business.
Boudreau Philip P bought 5,550 shares of ABT for $746,758 on Aug 08 ’25. On Apr 30 ’25, another insider, Blount Sally E., who serves as the Director of the company, sold 2,600 shares for $129.66 each. As a result, the insider received 337,116 and left with 34,058 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ABT now has a Market Capitalization of 237781499904 and an Enterprise Value of 244233502720. As of this moment, Abbott’s Price-to-Earnings (P/E) ratio for their current fiscal year is 17.09, and their Forward P/E ratio for the next fiscal year is 24.08. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.66. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.52 while its Price-to-Book (P/B) ratio in mrq is 4.70. Its current Enterprise Value per Revenue stands at 5.665 whereas that against EBITDA is 21.325.
Stock Price History:
The Beta on a monthly basis for ABT is 0.70, which has changed by 0.20539963 over the last 52 weeks, in comparison to a change of 0.1675967 over the same period for the S&P500. Over the past 52 weeks, ABT has reached a high of $141.23, while it has fallen to a 52-week low of $110.86. The 50-Day Moving Average of the stock is 4.66%, while the 200-Day Moving Average is calculated to be 6.34%.
Shares Statistics:
The stock has traded on average 6.49M shares per day over the past 3-months and 6015230 shares per day over the last 10 days, according to various share statistics. A total of 1.74B shares are outstanding, with a floating share count of 1.73B. Insiders hold about 0.67% of the company’s shares, while institutions hold 80.15% stake in the company. Shares short for ABT as of 1756425600 were 17753634 with a Short Ratio of 2.74, compared to 1753920000 on 18325255. Therefore, it implies a Short% of Shares Outstanding of 17753634 and a Short% of Float of 1.0199999.
Dividends & Splits
In the trailing 12 months, ABT’s forward annual dividend rate was 2.32, compared to 2.32 this year. Against a Trailing Annual Dividend Yield of 0.017053807. The stock’s 5-year Average Dividend Yield is 1.69. The current Payout Ratio is 29.33% for ABT, which recently paid a dividend on 2025-07-15 with an ex-dividend date of 2025-10-15. Stock splits for the company last occurred on 2013-01-02 when the company split stock in a 10000:4798 ratio.
Earnings Estimates
The market rating of Abbott Laboratories (ABT) is currently shaped by the ongoing analysis conducted by 23.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is $1.49, with high estimates of $1.51 and low estimates of $1.43.
Analysts are recommending an EPS of between $5.16 and $5.08 for the fiscal current year, implying an average EPS of $5.14. EPS for the following year is $5.67, with 27.0 analysts recommending between $5.77 and $5.56.
Revenue Estimates
23 analysts predict $11.4B in revenue for the current quarter. It ranges from a high estimate of $11.5B to a low estimate of $11.22B. As of the current estimate, Abbott Laboratories’s year-ago sales were $10.63BFor the next quarter, 23 analysts are estimating revenue of $11.78B. There is a high estimate of $11.94B for the next quarter, whereas the lowest estimate is $11.62B.
A total of 27 analysts have provided revenue estimates for ABT’s current fiscal year. The highest revenue estimate was $45.1B, while the lowest revenue estimate was $44.1B, resulting in an average revenue estimate of $44.68B. In the same quarter a year ago, actual revenue was $41.95BBased on 27 analysts’ estimates, the company’s revenue will be $48.16B in the next fiscal year. The high estimate is $48.86B and the low estimate is $47.09B.
